- European Medicines Agency's advisory committee issued a positive opinion recommending the approval of Myovant Sciences Ltd's MYOV Ryeqo (relugolix, estradiol, and norethindrone acetate) for uterine fibroids.
- The final decision on the application is expected to be available in approximately two months.
- Gedeon Richter will commercialize Ryeqo for uterine fibroids, if approved, in Europe under an agreement announced in March 2020.
- Relugolix combination tablet for uterine fibroids is also under review by the FDA with a target action date of June 1.
- Price Action: MYOV shares are up 2.56% at $22.81 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAMoversTrading IdeasGeneralBriefsEuropean Medicines Agency (EMA)Uterine Fibroids
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
